ENTERA BIO LTD. (ENTX) Current Ratio
- Current ratio · latest quarter: Value 8.98×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 8.98× | Current assets / current liabilities. $18.90M ÷ $2.10M ≈ 8.98× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 18.90M USD | Assets, Current |
| Current obligations | 2.10M USD | Liabilities, Current |
| Cash and equivalents | 11.31M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 575.00K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.90M | $2.10M | $11.31M | (m) | (m) | (m) | $575.00K | (m) | 8.98× |
| 2026-03-31 | $12.49M | $1.58M | $4.14M | (m) | (m) | (m) | $274.00K | (m) | 7.93× |
| 2025-12-31 | $15.30M | $2.20M | $7.11M | (m) | (m) | (m) | $448.00K | (m) | 6.94× |
| 2025-09-30 | $17.01M | $1.57M | $8.57M | (m) | $0.00 | (m) | $216.00K | (m) | 10.83× |
| 2025-06-30 | $19.31M | $1.84M | $10.86M | (m) | $0.00 | (m) | $383.00K | (m) | 10.47× |
| 2025-03-31 | $21.22M | $1.62M | $12.57M | (m) | $126.00K | (m) | $134.00K | (m) | 13.07× |
| 2024-12-31 | $8.97M | $1.18M | $8.66M | (m) | $126.00K | (m) | $132.00K | (m) | 7.63× |
| 2024-09-30 | $7.34M | $1.11M | $6.92M | (m) | $42.00K | (m) | $184.00K | (m) | 6.61× |
| 2024-06-30 | $9.60M | $1.29M | $9.06M | (m) | $57.00K | (m) | $69.00K | (m) | 7.41× |
| 2024-03-31 | $9.75M | $1.12M | $9.19M | (m) | (m) | (m) | $66.00K | (m) | 8.70× |
| 2023-12-31 | $11.26M | $1.09M | $11.02M | (m) | $0.00 | (m) | $83.00K | (m) | 10.32× |
| 2023-09-30 | $8.02M | $2.03M | $7.58M | (m) | $0.00 | (m) | $564.00K | (m) | 3.95× |
| 2023-06-30 | $9.81M | $1.86M | $9.13M | (m) | $29.00K | (m) | $240.00K | (m) | 5.26× |
| 2023-03-31 | $11.37M | $1.49M | $10.69M | (m) | $29.00K | (m) | $150.00K | (m) | 7.61× |
| 2022-12-31 | $12.85M | $1.34M | $12.31M | (m) | $246.00K | (m) | $17.00K | (m) | 9.58× |
| 2022-09-30 | $15.19M | $1.19M | $14.32M | (m) | $233.00K | (m) | $413.00K | (m) | 12.73× |
| 2022-06-30 | $18.43M | $1.69M | $17.28M | (m) | $225.00K | (m) | $109.00K | (m) | 10.89× |
| 2022-03-31 | $21.64M | $2.33M | $20.11M | (m) | $210.00K | (m) | $199.00K | (m) | 9.27× |
| 2021-12-31 | $25.33M | $3.16M | $24.89M | (m) | $183.00K | (m) | $166.00K | (m) | 8.01× |
| 2020-12-31 | $9.11M | $1.84M | $8.59M | (m) | $255.00K | (m) | $164.00K | (m) | 4.95× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |